ArticleNature reviews. Clinical oncology2010
A case of variant angina in a patient under chronic treatment with sorafenib.
Article in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Major Adverse Cardiovascular Events in Angiogenesis Inhibitor-Based Cancer Therapy: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.Biomedicines · 2023Review
- Cardiotoxic effects of angiogenesis inhibitors.Clinical science (London, England : 1979) · 2021Review
- Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review.Journal of liver cancer · 2020Article
- Optimal management of coronary artery disease in cancer patients.Chronic diseases and translational medicine · 2019Review
- Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Molecular and clinical oncology · 2017Article
- Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?Current oncology reports · 2016Review
- Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Journal of gastrointestinal oncology · 2016Article
- Review
- Sorafenib cardiotoxicity increases mortality after myocardial infarction.Circulation research · 2014Article
- Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.BMJ case reports · 2013Article
- Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.BMC cancer · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA 63-year-old man with an unresectable multifocal hepatocellular carcinoma (HCC) presented with upper abdominal discomfort, nausea and vomiting. We report a case of variant angina in a patient affected by unresectable HCC under chronic treatment with sorafenib. Spontaneous spasm occurred during cardiac catheterization and was revealed during coronary angiogram with the unusual feature of a retrograde transient filling of a contralateral branch. INVESTIGATIONS: Electrocardiogram, cardiac catheterization, chest X-ray, emergency ECG. DIAGNOSIS: Variant angina induced by sorafenib treatment mimicking infero-posterior ST-elevation myocardial infarction (STEMI). MANAGEMENT: High-dose calcium-antagonists and nitrates were initially given intravenously and then orally. Sorafenib therapy was then resumed without further symptoms. Restaging of the cancer revealed unexpected local recurrence and the patient died 1 month after receiving palliative care. We contend that the effects of sorafenib treatment were primarily responsible for the major cardiovascular event observed in this case, and it is important for clinicians to be aware of this possible severe complication of sorafenib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.